Meeting
2018 ASCO Annual Meeting
An individual patient level data pooled analysis of T-DM1 cardiac safety in HER2-positive (HER2+) metastatic breast cancer (MBC) patients.
Authors
Noam Falbel Ponde
Centro Paulista de Oncologia, Sao Paulo, Brazil
Noam Falbel Ponde , Lieveke Ameye , Matteo Lambertini , Marianne Paesmans , Evandro De Azambuja
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Patient and Survivor Care
Track
Patient and Survivor Care
Sub Track
Late and Long-Term Effects
Citation
J Clin Oncol 36, 2018 (suppl; abstr 10068)
DOI
10.1200/JCO.2018.36.15_suppl.10068
Abstract #
10068
Poster Bd #
56
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Breakthrough
Retrospective observational study of outcomes in HER2-positive metastatic breast cancer patients treated with trastuzumab emtansine in single center.
First Author: WanChen Hsieh
Poster
2022 ASCO Annual Meeting
Survival of elderly patients with HER2+/HR- metastatic breast cancer in clinical practice: SEER-Medicare data 2012-2016.
First Author: Zhonghui Ou
Poster
2021 ASCO Annual Meeting
Updated results of tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB).
First Author: Giuseppe Curigliano
Poster
2020 ASCO Virtual Scientific Program
A phase Ib study of pembrolizumab (pembro) plus trastuzumab emtansine (T-DM1) for metastatic HER2+ breast cancer (MBC).
First Author: Adrienne Gropper Waks